Mcdougall B, King P J, Wu B W, et al. Dicaffeoylquinic and dicaffeoyltartaric acids are selective inhibitors of human immunodeficiency virus type 1 integrase [J]. Antimicrob Agents Chemother, 1998, 42: 140.
[2]
Reinke R A, Lee D J, Mcdougall B R, et al. L-chicoric acid inhibits human immunodeficiency virus type 1 integration in vivo and is a noncompetitive but reversible inhibitor of HIV-1 integrase in vitro [J]. Virology, 2004, 326: 203.
[3]
Liu J, Fan D. Hepatitis B in China [J]. Lancet, 2007, 369: 1582.
[4]
陈鸿珊,张兴权.抗病毒药物及其研究方法[M].2版.北京:化学工业出版社, 2013:545.
[5]
Seeger C, Mason W S. Hepatitis B virus biology [J]. Microbiol Mol Biol Rev, 2000, 64: 51.
[6]
Korba B E, Milman G. A cell culture assay for compounds which inhibit hepatitis B virus replication [J]. Antiviral Res, 1991, 15: 217.
[7]
Farza H, Salmon A M, Hadchouel M. Hepatitis B surface antigen gene expression is regulated by sex steroids and glucocorticoids in transgenic mice [J]. Proc Natl Acad Sci USA, 1987, 84: 1187.
[8]
Guidotti L G, Matzke B, Schaller H. High-level hepatitis B virus replication in transgenic mice [J]. J Virol, 1995, 69: 6158.
[9]
Stross L, Gunther J, Gasteiger G, et al. Foxp3+ regulatory T cells protect the liver from immune damage and compromise virus control during acute, experimental hepatitis B virus infection [J]. Hepatology, 2012, 56: 873.
[10]
Raziorrouh B, Schraut W, Gerlach T, et al. The immunoregulatory role of CD244 in chronic hepatitis B infection and its inhibitory potential on virus specific CD8+ T-cell function [J]. Hepatology, 2010, 52: 1934.
[11]
Chisari F V, Pinkert C A, Milich D R, et al. A transgenic mouse model of the chronic hepatitis B surface antigen carrier state [J]. Science, 1985, 230: 1157.
Abd-Elazem I S, Chen H S, Bates R B, et al. Isolation of two highly potent and non-toxic inhibitors of human immunodeficiency virus type 1(HIV-1)integrase from Salvia miltiorrhiza [J]. Antiviral Res, 2002, 55: 91.
[14]
Mazumder A, Neamati N, Sunder S, et al. Curcumin analogs with altered potencies against HIV-1 integrase as probes for biochemical mechanisms of drug action [J]. J Med Chem, 1997, 40: 3057.
[15]
Stoll A, Renz J, Brack A. Isolation and constitution of echinacoside, a glycoside from the Echinacea angustifolia DC [J]. Helv Chim Acta, 1950, 33: 1877.
[16]
Li X, Gou C, Yang H, et al. Echinacoside ameliorates D-galactosamine plus lipopolysaccharide-induced acute liver injury in mice via inhibition of apoptosis and inflammation [J]. Scand J Gastroenterol, 2014, 49: 993.
[17]
Kuang R, Sun Y, Zheng X. Suppression of nitric oxide implicated in the protective effect of echinacoside on H2O2-induced PC12 cell injury [J]. Nat Prod Commun, 2010, 5: 571.
[18]
Zhang Y, Xing J, Ai T, et al. Protection of echinacoside against acute lung injury caused by oleic acid in rats [J]. Free Radic Res, 2007, 41: 798.
[19]
Geng X, Tian X, Tu P, et al. Neuroprotective effects of echinacoside in the mouse MPTP model of Parkinson\'s disease [J]. Eur J Pharmacol, 2007, 564: 66.
[20]
Cheminat A, Zawatzky R, Becker H, et al. Caffeoyl conjugates from Echinacea species: structures and biological activity [J]. Phytochemistry, 1988, 27: 2787.
